Price
No data yet.
Social Signal Score
Analyst Ratings
5 analystsRevenue
$0.00-100.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- R. Nolan Townsend
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 63
- Beta
- 1.50
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- 6.08
Financials
Revenue
$0.00-100.0%Net Income
$-25.87MEBITDA
$-25.78MFree Cash Flow
$-17.60MEPS (diluted)
$-0.30Shares Outstanding (diluted)
85.63M+221.3%Operating Expenses
$28.02MCash & Debt
$211.70MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-99.96M | $-1.86 |
| 2024 | $0.00 | $-98.33M | $-3.09 |
| 2023 | $0.00 | $-66.39M | $-2.49 |
| 2022 | $654.0K | $-59.28M | $-2.36 |
| 2021 | $1.66M | $-50.62M | $-2.01 |
| 2020 | $518.5K | $-5.15M | $-0.20 |
Valuation
LXEOhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50-28.57%Social Signal Score
Mentions (7)
- Newsglobenewswire.com·5d ago·Neutral
…alyses providing additional insight into neurologic outcomes following LX2006 treatment NEW YORK, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, announced today its abstract has been accepted to be presented at the International Congress of Parkinson's Disease and Movement Disorders 2026 taking place October 4-8, 2026 in Seoul, Korea. “We are pleased to see LX2006 featured…
View source ↗ - Newsprnewswire.com·13d ago·Positive
…pertura Gene Therapy, a biotechnology company developing next-generation AAV capsids for delivering genetic medicines, will provide Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, access to TfR1 CapX™ for a program designed to treat Friedreich ataxia.
View source ↗ - Newsglobenewswire.com·13d ago·Positive
Lexeo Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum NEW YORK, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, today announced that the Company will participate in a fireside chat at the Stifel 2026 Virtual Cardiometabolic Forum on September 30, 2026 at 9:00am ET.
View source ↗ - Newsseekingalpha.com·13d ago·Positive
Lexeo Therapeutics, Inc. (LXEO) M&A Call Transcript Lexeo Therapeutics, Inc. (LXEO) M&A Call Transcript
View source ↗ - Newsglobenewswire.com·14d ago·Positive
…es while maintaining cash runway into 2028 Company to host webcast today at 8:00 AM ET NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, today announced a series of strategic transactions to expand its presence in Friedreich ataxia (FA), including the signing of a definitive agreement to acquire Mantle Therapeutics Inc. and three new research collaborations support…
View source ↗ - Newsglobenewswire.com·34d ago·Neutral
Lexeo Therapeutics to Participate in Upcoming Investor Conferences in September NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that members of management will participate in the following investor conferences in September: Cantor Global Healthcare Conference 2026.
View source ↗ - Newsglobenewswire.com·55d ago·Positive
Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights Finalized SUNRISE-FA 2 open-label, pivotal trial protocol and SAP for LX2006 in support of accelerated approval pathway; topline data expected in second half of 2027 Initiated SUNRISE-FA 2 with first patient enrolled into pivotal study in June; site activation efforts ongoing CLARITY-FA enrollment continues to advance, supporting identification of eligible participants for SUNRISE-FA 2 FDA granted RMAT de
View source ↗
Earnings
Mon, Dec 14(in 2 months)
Consensus estimate $-0.32 per share
Typical surprise +10.3% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 12$-0.30 vs $-0.29miss
- Mon, May 11$-0.25 vs $-0.29beat
- Mon, Mar 30$-0.27 vs $-0.32beat
- Wed, Nov 5$-0.33 vs $-0.48beat
- Thu, Aug 14$-0.60 vs $-0.64beat
- Mon, May 12$-0.99 vs $-0.80miss
Estimates and results for LXEO via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by LXEO officers and directors.
- Bought
- —
- Sold
- $1.1m
0 trades
41 trades
- Tamayo Louis Edwardsold
- Townsend Richard Nolansold
- Otero Jose Manuelsold
- Tamayo Louis Edwardsold
- Otero Jose Manuelsold
- Bhalla Narinder Palsold
- Townsend Richard Nolansold
- Otero Jose Manuelsold
59 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in LXEO.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.